Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Preclinical and Clinical Evidence of Immune Responses Triggered in Oncologic Photodynamic Therapy: Clinical Recommendations.

Beltrán Hernández I, Yu Y, Ossendorp F, Korbelik M, Oliveira S.

J Clin Med. 2020 Jan 24;9(2). pii: E333. doi: 10.3390/jcm9020333. Review.

2.

N-dihydrogalactochitosan-supported tumor control by photothermal therapy and photothermal therapy-generated vaccine.

Korbelik M, Banáth J, Zhang W, Hode T, Lam SSK, Gallagher P, Zhao J, Zeng H, Chen WR.

J Photochem Photobiol B. 2020 Jan 7;204:111780. doi: 10.1016/j.jphotobiol.2020.111780. [Epub ahead of print]

PMID:
31981988
3.

N-dihydrogalactochitosan as immune and direct antitumor agent amplifying the effects of photodynamic therapy and photodynamic therapy-generated vaccines.

Korbelik M, Banáth J, Zhang W, Gallagher P, Hode T, Lam SSK, Chen WR.

Int Immunopharmacol. 2019 Oct;75:105764. doi: 10.1016/j.intimp.2019.105764. Epub 2019 Jul 25.

PMID:
31352327
4.

Role of cell stress signaling networks in cancer cell death and antitumor immune response following proteotoxic injury inflicted by photodynamic therapy.

Korbelik M.

Lasers Surg Med. 2018 Jul;50(5):491-498. doi: 10.1002/lsm.22810. Epub 2018 Mar 7. Review.

PMID:
29512168
5.

Fumonisin B1 Inhibits Endoplasmic Reticulum Stress Associated-apoptosis After FoscanPDT Combined with C6-Pyridinium Ceramide or Fenretinide.

Boppana NB, Kraveka JM, Rahmaniyan M, Li LI, Bielawska A, Bielawski J, Pierce JS, Delor JS, Zhang K, Korbelik M, Separovic D.

Anticancer Res. 2017 Feb;37(2):455-463.

6.
7.

Interaction of acid ceramidase inhibitor LCL521 with tumor response to photodynamic therapy and photodynamic therapy-generated vaccine.

Korbelik M, Banáth J, Zhang W, Saw KM, Szulc ZM, Bielawska A, Separovic D.

Int J Cancer. 2016 Sep 15;139(6):1372-8. doi: 10.1002/ijc.30171. Epub 2016 May 18.

8.

Enhanced apoptotic cancer cell killing after Foscan photodynamic therapy combined with fenretinide via de novo sphingolipid biosynthesis pathway.

Boppana NB, DeLor JS, Van Buren E, Bielawska A, Bielawski J, Pierce JS, Korbelik M, Separovic D.

J Photochem Photobiol B. 2016 Jun;159:191-5. doi: 10.1016/j.jphotobiol.2016.02.040. Epub 2016 Mar 16.

9.

Immunoregulatory Cell Depletion Improves the Efficacy of Photodynamic Therapy-Generated Cancer Vaccines.

Korbelik M, Banáth J, Saw KM.

Int J Mol Sci. 2015 Nov 12;16(11):27005-14. doi: 10.3390/ijms161126008.

10.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

11.

Enhanced killing of SCC17B human head and neck squamous cell carcinoma cells after photodynamic therapy plus fenretinide via the de novo sphingolipid biosynthesis pathway and apoptosis.

Boppana NB, Stochaj U, Kodiha M, Bielawska A, Bielawski J, Pierce JS, Korbelik M, Separovic D.

Int J Oncol. 2015 May;46(5):2003-10. doi: 10.3892/ijo.2015.2909. Epub 2015 Feb 26.

12.

Calreticulin as cancer treatment adjuvant: combination with photodynamic therapy and photodynamic therapy-generated vaccines.

Korbelik M, Banáth J, Saw KM, Zhang W, Čiplys E.

Front Oncol. 2015 Feb 3;5:15. doi: 10.3389/fonc.2015.00015. eCollection 2015.

13.

C6-pyridinium ceramide sensitizes SCC17B human head and neck squamous cell carcinoma cells to photodynamic therapy.

Boppana NB, Stochaj U, Kodiha M, Bielawska A, Bielawski J, Pierce JS, Korbelik M, Separovic D.

J Photochem Photobiol B. 2015 Feb;143:163-8. doi: 10.1016/j.jphotobiol.2015.01.001. Epub 2015 Jan 10.

14.

The impact of macrophage-cancer cell interaction on the efficacy of photodynamic therapy.

Korbelik M, Hamblin MR.

Photochem Photobiol Sci. 2015 Aug;14(8):1403-9. doi: 10.1039/c4pp00451e. Epub 2015 Jan 26.

15.

Ceramide synthase inhibitor fumonisin B1 inhibits apoptotic cell death in SCC17B human head and neck squamous carcinoma cells after Pc4 photosensitization.

Boppana NB, Kodiha M, Stochaj U, Lin HS, Haimovitz-Friedman A, Bielawska A, Bielawski J, Divine GW, Boyd JA, Korbelik M, Separovic D.

Photochem Photobiol Sci. 2014 Nov;13(11):1621-7. doi: 10.1039/c4pp00292j.

16.

Ceramide and sphingosine-1-phosphate act as photodynamic therapy-elicited damage-associated molecular patterns: cell surface exposure.

Korbelik M, Banáth J, Sun J, Canals D, Hannun YA, Separovic D.

Int Immunopharmacol. 2014 Jun;20(2):359-65. doi: 10.1016/j.intimp.2014.03.016. Epub 2014 Apr 5.

17.

Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation.

Separovic D, Breen P, Boppana NB, Van Buren E, Joseph N, Kraveka JM, Rahmaniyan M, Li L, Gudz TI, Bielawska A, Bai A, Bielawski J, Pierce JS, Korbelik M.

Int J Oncol. 2013 Dec;43(6):2064-72. doi: 10.3892/ijo.2013.2132. Epub 2013 Oct 9.

18.

Cationic ceramides and analogues, LCL30 and LCL85, as adjuvants to photodynamic therapy of tumors.

Korbelik M, Zhang W, Saw KM, Szulc ZM, Bielawska A, Separovic D.

J Photochem Photobiol B. 2013 Sep 5;126:72-7. doi: 10.1016/j.jphotobiol.2013.06.013. Epub 2013 Jul 6.

19.

Upregulation of genes for C-reactive protein and related pentraxin/complement proteins in photodynamic therapy-treated human tumor cells: enrolment of PI3K/Akt and AP-1.

Merchant S, Korbelik M.

Immunobiology. 2013 Jun;218(6):869-74. doi: 10.1016/j.imbio.2012.10.010. Epub 2012 Oct 26.

PMID:
23182717
20.

Monitoring ceramide and sphingosine-1-phosphate levels in cancer cells and macrophages from tumours treated by photodynamic therapy.

Korbelik M, Zhang W, Separovic D.

Photochem Photobiol Sci. 2012 May;11(5):779-84. doi: 10.1039/c2pp05384e. Epub 2012 Feb 22.

PMID:
22354109
21.

Photodynamic therapy-generated cancer vaccine elicits acute phase and hormonal response in treated mice.

Korbelik M, Merchant S.

Cancer Immunol Immunother. 2012 Sep;61(9):1387-94. doi: 10.1007/s00262-012-1206-8. Epub 2012 Jan 24.

PMID:
22270715
22.

Full range characterization of the Raman spectra of organs in a murine model.

Huang N, Short M, Zhao J, Wang H, Lui H, Korbelik M, Zeng H.

Opt Express. 2011 Nov 7;19(23):22892-909. doi: 10.1364/OE.19.022892.

PMID:
22109167
23.

Antitumor efficacy of photodynamic therapy using novel nanoformulations of hypocrellin photosensitizer SL052.

Korbelik M, Madiyalakan R, Woo T, Haddadi A.

Photochem Photobiol. 2012 Jan-Feb;88(1):188-93. doi: 10.1111/j.1751-1097.2011.01035.x. Epub 2011 Dec 20.

PMID:
22070614
24.

Amplification of cancer cell apoptosis in photodynamic therapy-treated tumors by adjuvant ceramide analog LCL29.

Korbelik M, Zhang W, Separovic D.

Lasers Surg Med. 2011 Sep;43(7):614-20. doi: 10.1002/lsm.21068.

PMID:
22057489
25.

Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release.

Korbelik M, Zhang W, Merchant S.

Cancer Immunol Immunother. 2011 Oct;60(10):1431-7. doi: 10.1007/s00262-011-1047-x. Epub 2011 Jun 5.

PMID:
21644033
26.

Photodynamic therapy of cancer: an update.

Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J.

CA Cancer J Clin. 2011 Jul-Aug;61(4):250-81. doi: 10.3322/caac.20114. Epub 2011 May 26. Review.

27.

Drug delivery technologies and immunological aspects of photodynamic therapy.

Berg K, Golab J, Korbelik M, Russell D.

Photochem Photobiol Sci. 2011 May;10(5):647-8. doi: 10.1039/c1pp90010b. Epub 2011 Apr 13. No abstract available.

PMID:
21487635
28.

Cancer vaccines generated by photodynamic therapy.

Korbelik M.

Photochem Photobiol Sci. 2011 May;10(5):664-9. doi: 10.1039/c0pp00343c. Epub 2011 Jan 24.

PMID:
21258728
29.

Enhanced tumor cures after Foscan photodynamic therapy combined with the ceramide analog LCL29. Evidence from mouse squamous cell carcinomas for sphingolipids as biomarkers of treatment response.

Separovic D, Bielawski J, Pierce JS, Merchant S, Tarca AL, Bhatti G, Ogretmen B, Korbelik M.

Int J Oncol. 2011 Feb;38(2):521-7. doi: 10.3892/ijo.2010.863. Epub 2010 Dec 6.

30.

Single-wall carbon nanotubes assisted photothermal cancer therapy: animal study with a murine model of squamous cell carcinoma.

Huang N, Wang H, Zhao J, Lui H, Korbelik M, Zeng H.

Lasers Surg Med. 2010 Nov;42(9):638-48. doi: 10.1002/lsm.20968.

PMID:
20949599
31.

Expression of complement and pentraxin proteins in acute phase response elicited by tumor photodynamic therapy: the engagement of adrenal hormones.

Merchant S, Huang N, Korbelik M.

Int Immunopharmacol. 2010 Dec;10(12):1595-601. doi: 10.1016/j.intimp.2010.09.015. Epub 2010 Oct 8.

PMID:
20933626
32.

Heat shock protein 70 is acute phase reactant: response elicited by tumor treatment with photodynamic therapy.

Merchant S, Korbelik M.

Cell Stress Chaperones. 2011 Mar;16(2):153-62. doi: 10.1007/s12192-010-0227-5. Epub 2010 Sep 24.

33.

Photodynamic therapy-generated cancer vaccines.

Korbelik M.

Methods Mol Biol. 2010;635:147-53. doi: 10.1007/978-1-60761-697-9_11.

PMID:
20552346
34.

Exploitation of immune response-eliciting properties of hypocrellin photosensitizer SL052-based photodynamic therapy for eradication of malignant tumors.

Korbelik M, Merchant S, Huang N.

Photochem Photobiol. 2009 Nov-Dec;85(6):1418-24. doi: 10.1111/j.1751-1097.2009.00610.x.

PMID:
19709384
35.

Complement upregulation in photodynamic therapy-treated tumors: Role of Toll-like receptor pathway and NFkappaB.

Korbelik M.

Cancer Lett. 2009 Aug 28;281(2):232-8. doi: 10.1016/j.canlet.2009.02.049. Epub 2009 Mar 27.

PMID:
19328626
36.

Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas.

Separovic D, Bielawski J, Pierce JS, Merchant S, Tarca AL, Ogretmen B, Korbelik M.

Br J Cancer. 2009 Feb 24;100(4):626-32. doi: 10.1038/sj.bjc.6604896.

37.

Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy.

Korbelik M, Cecic I.

J Photochem Photobiol B. 2008 Oct 16;93(1):53-9. doi: 10.1016/j.jphotobiol.2008.04.005. Epub 2008 Apr 26.

PMID:
18715798
38.

Dying cells program their expedient disposal: serum amyloid P component upregulation in vivo and in vitro induced by photodynamic therapy of cancer.

Merchant S, Sun J, Korbelik M.

Photochem Photobiol Sci. 2007 Dec;6(12):1284-9. Epub 2007 Sep 18.

PMID:
18046483
39.

Acute phase response induction by cancer treatment with photodynamic therapy.

Korbelik M, Cecic I, Merchant S, Sun J.

Int J Cancer. 2008 Mar 15;122(6):1411-7.

40.

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression.

Korbelik M, Stott B, Sun J.

Br J Cancer. 2007 Nov 19;97(10):1381-7. Epub 2007 Oct 30.

41.

The impact of complement activation on tumor oxygenation during photodynamic therapy.

Cecic I, Minchinton AI, Korbelik M.

Photochem Photobiol. 2007 Sep-Oct;83(5):1049-55.

PMID:
17880499
42.

Potentiation of photodynamic therapy of cancer by complement: the effect of gamma-inulin.

Korbelik M, Cooper PD.

Br J Cancer. 2007 Jan 15;96(1):67-72. Epub 2006 Dec 5.

43.

Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy.

Stott B, Korbelik M.

Cancer Immunol Immunother. 2007 May;56(5):649-58. Epub 2006 Sep 1.

PMID:
16947020
44.

Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy.

Cecic I, Stott B, Korbelik M.

Int Immunopharmacol. 2006 Aug;6(8):1259-66. Epub 2006 Apr 19.

PMID:
16782538
45.

PDT-associated host response and its role in the therapy outcome.

Korbelik M.

Lasers Surg Med. 2006 Jun;38(5):500-8. Review.

PMID:
16634073
46.
47.

Photoimmunotherapy for cancer treatment.

Chen WR, Huang Z, Korbelik M, Nordquist RE, Liu H.

J Environ Pathol Toxicol Oncol. 2006;25(1-2):281-91. Review.

PMID:
16566724
48.

Deposition of complement proteins on cells treated by photodynamic therapy in vitro.

Cecic I, Korbelik M.

J Environ Pathol Toxicol Oncol. 2006;25(1-2):189-203.

PMID:
16566717
49.

Photodynamic therapy-generated vaccine for cancer therapy.

Korbelik M, Sun J.

Cancer Immunol Immunother. 2006 Aug;55(8):900-9. Epub 2005 Oct 8.

PMID:
16215717
50.

Characteristics of complement activation in mice bearing Lewis lung carcinomas treated by photodynamic therapy.

Cecic I, Serrano K, Gyongyossy-Issa M, Korbelik M.

Cancer Lett. 2005 Jul 28;225(2):215-23. Epub 2005 Jan 13.

PMID:
15978326

Supplemental Content

Loading ...
Support Center